Background: Biologic drugs act by suppressing synovitis in patients with rheumatoid arthritis (RA). Clinical disease activity scores (DAS) are used to determine eligibility and assess biologic drug response. However, several drivers aside from synovitis may drive the DAS. Joint ultrasound (US) scan is more accurate than clinical examination in detecting inflammatory synovitis [1, 2] , and is frequently used in clinical practice to assess need for biologic drug change [3] . Objectives: To phenotype DAS using US in patients eligible for a first/switch in biologic therapy and to evaluate whether and how this changed decision making. Methods: A retrospective evaluation of RA patients who attended our tertiary centre biologic clinic between 2014 and 2016 and had an US to clarify basis for raised disease activity. Three-variable DAS28-CRP 28 joints (DAS28-CRP) was recorded and US reports were evaluated to determine which of the following characteristics were observed: presence of synovitis, tenosynovitis, osteoarthritis, tendinopathy and no abnormality. Clinic notes were reviewed to record change in the management of patients as a result of combined clinical and US scan findings. Results: We identified 70 patients who had not received steroids within 4 weeks of the US, 84.3% female, median (range) age 58 (20-88) years. 66 (94.3%) patients were biologic experienced with 59 on ongoing treatment [3 (5.1%) abatacept, 22 (37.3%) anti-TNFα, 22 (37.3%) rituximab and 12 (20.3%) tocilizumab] of whom 47 (79.7%) were on combination with csDMARD therapy. 4 (5.7%) patients were biologic naive. 42 (63.6%) of bio-experienced patients, had a DAS28 ≥3.2 and were eligible for a change in their biologic however, only 17 of these patients had US-confirmed synovitis, 21 had evidence of osteoarthritis (OA), 1 tenosynovitis and 3 had no abnormalities. All biologic naïve patients had DAS28-CRP ≤5.1 before US however, 3 had US-confirmed synovitis and 1 had OA. Of bio-experienced, 13/66 (19.4%) patients, including 4 with DAS-28 <3.2 but US-confirmed synovitis, had a new biologic started. 3 rituximab patients (including one with subclinical synovitis) had re-treatment. Concomitant treatment was escalated in 13 (24.2%) patients. 35 (53.0%) patients, including 4 with US synovitis/tenosynovitis, had no change in their treatment. 2 (3.0%) patients self-discontinued treatment. Conclusions: By identifying lack of inflammatory synovitis in biologic eligible patients US reduced the need for unnecessary and costly change of biologics. US also detected subclinical synovitis warranting modification of their treatment. Objectives: To evaluate the diagnostic utility of detecting enthesitis by ultrasound in patients with peripheral spondyloarthritis (SpA). Methods: A single-center cohort study was performed in patients with symptoms suggestive of peripheral SpA (inflammatory back pain, arthritis of the lower limbs, tenderness of the entheses and dactylitis). Patients with only axial symptoms in the absence of peripheral symptoms were excluded. Fourteen sites of enthesis (both sides of lateral epicondyle, quadriceps tendon insertion into the patella, patellar ligament insertion into the patella and tibial tuberosity, medial and lateral femoral condyles, and Achilles tendon) were assessed at baseline by ultrasound. Ultrasound assessment was made by Japan College of Rheumatology (JCR)-registered sonographers. Furthermore, articular synovitis and tenosynovitis of both wrist and finger joints as well as symptomatic sites were examined. Clinical, laboratory (CRP, HLA typing), radiological (X-ray and MRI of sacroiliac joint) findings and SpA classification criteria (Amor's, ESSG and ASAS) were also evaluated. The gold standard was the diagnosis made by the JCR-certified rheumatologists during a six-month follow-up period. Results: Between April 2014 and November 2016, one hundred-thirty six patients were consecutively enrolled. A definite diagnosis was obtained in 112 patients (72 SpA and 40 non-SpA). Diagnosis was not made in the remaining 24 patients. Seventy-two SpA patients (62 with undifferentiated SpA, 6 with psoriatic arthritis, 2 with AS, 1 with inflammatory bowel disease-associated arthritis and 1 with reactive arthritis) and 40 non-SpA patients were investigated in this study. In ultrasound findings, SpA patients showed power Doppler (PD) signals of the articular synovium (57%), tendon sheath synovium (71%) and enthesis (94%). A PD signal for at least one enthesis sites was the most useful finding for differentiation of SpA from non-SpA (sensitivity 94%; specificity 85%; accuracy 91%; positive likelihood ratio 6.3) regarding ultrasound findings. In logistic regression analysis, fulfillment of peripheral ASAS criteria, that of Amor's criteria, and presence of PD signals at least one enthesis sites were independent variables to the contribution of diagnosis of SpA (Figure 1 ).
